Please wait while the formulary information is being retrieved.
KRYSTEXXA (PEGLOTICASE)
- Prevention of acute gout attack
8 mg/mL intravenous solution
- Dosage information is not available
Prevention of acute gout attack
- Infuse 1 milliliter (8 mg) ,diluted in 250 ml of 0.9 % nacl, over no less than 120 minute(s) by intravenous route every 2 weeks
- Infuse 1 milliliter (8 mg) ,diluted in 250 ml of 0.45 % nacl, over noless than 120 minute(s) by intravenous route every 2 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Hemolytic anemia from PK and g6PD deficiencies
Contraindicated
- None
Severe
Moderate
- Chronic heart failure
KRYSTEXXA (PEGLOTICASE)
- Prevention of acute gout attack
- Anaphylaxis
- Chest discomfort
- Chest pain
- Dyspnea
- Erythema
- Hypersensitivity drug reaction
- Pruritus of skin
- Urticaria
- Acute gouty arthritis
- Constipation
- Ecchymosis
- Nausea
More Frequent
Severe
Less Severe
- None
- Pharyngitis
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Worsening of chronic heart failure
Less Severe
- General weakness
- Malaise
- Peripheral edema
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pegloticase
Safety and efficacy has not been established.
- 1 Day – 18 Years
- Safety and efficacy has not been established.
Pegloticase
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pegloticase
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Pegloticase may rarely cause a serious allergic reaction. This may occur during or after the infusion of the medication. Your doctor will check your blood before each treatment and monitor you closely during and after infusion.<br /><br />Your doctor should prescribe other medications (such as antihistamines, corticosteroids) to help prevent an allergic reaction. However, serious allergic reactions may still occur in a few patients. Get medical help right away if you develop any signs of an allergic reaction, such as rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing, chest discomfort/pain.<br /><br /> Do not use this medication if you have a certain metabolic disorder called glucose-6-phosphate dehydrogenase (G6PD) deficiency because it can severely damage your red blood cells leading to anemia (hemolysis). If you are of African, Mediterranean, or Southern Asian descent, you may be at higher risk for G6PD deficiency and should be tested to see if you have this condition before starting this medication.
| Prevention of acute gout attack | |
| E79.0 | Hyperuricemia without signs of inflammatory arthritis and tophaceous disease |
| M10 | Gout |
| M10.00 | Idiopathic gout, unspecified site |
| M10.30 | Gout due to renal impairment, unspecified site |
| M10.40 | Other secondary gout, unspecified site |
| M10.9 | Gout, unspecified |
| M1A.00x1 | Idiopathic chronic gout, unspecified site, with tophus (tophi) |
| M1A.20x1 | Drug-induced chronic gout, unspecified site, with tophus (tophi) |
| M1A.30x1 | Chronic gout due to renal impairment, unspecified site, with tophus (tophi) |
| M1A.40x1 | Other secondary chronic gout, unspecified site, with tophus (tophi) |
| M1A.9xx0 | Chronic gout, unspecified, without tophus (tophi) |
| M1A.9xx1 | Chronic gout, unspecified, with tophus (tophi) |
| 0-9 | A-Z |
|---|---|
| E79.0 | Hyperuricemia without signs of inflammatory arthritis and tophaceous disease |
| M10 | Gout |
| M10.00 | Idiopathic gout, unspecified site |
| M10.30 | Gout due to renal impairment, unspecified site |
| M10.40 | Other secondary gout, unspecified site |
| M10.9 | Gout, unspecified |
| M1A.00x1 | Idiopathic chronic gout, unspecified site, with tophus (tophi) |
| M1A.20x1 | Drug-induced chronic gout, unspecified site, with tophus (tophi) |
| M1A.30x1 | Chronic gout due to renal impairment, unspecified site, with tophus (tophi) |
| M1A.40x1 | Other secondary chronic gout, unspecified site, with tophus (tophi) |
| M1A.9xx0 | Chronic gout, unspecified, without tophus (tophi) |
| M1A.9xx1 | Chronic gout, unspecified, with tophus (tophi) |
Formulary Reference Tool